Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.30 |
| ▸ | FEN1 | P39748 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9927711 | 0.89 | NPC1 (0.31) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL9927704 | 0.85 | ALOX5 (0.33) | FFAR4 | |
| SCHEMBL9927703 | 0.85 | RAB9A (0.31) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL9927582 | 0.85 | FFAR4 (0.34) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL9927710 | 0.84 | — | — | |
| SCHEMBL9927712 | 0.83 | CSF1R (0.32) | — | |
| SCHEMBL12821228 | 0.83 | MPL (0.33) | FFAR4ALOX5APFEN1 | |
| SCHEMBL9927614 | 0.81 | FFAR4 (0.35) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL3582651 | 0.79 | MPL (0.36) | — | |
| SCHEMBL9927535 | 0.78 | RAB9A (0.37) | NPC1RAB9ASMN1; SMN2HSD17B10FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468740-B1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY DEVICES | JNC CORP (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9663716-B2 | Tetrahydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9663716-B2 | Tetrahydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2468740-A1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY ELEMENTS | JNC Corporation (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20120145958-A1 | TETRAHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120145958-A1 | TETRAHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145958-A1 | TETRAHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, CCND1, CCND2 | NPC1 2862/4885TP53 3330/4885RAB9A 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.